1. Home
  2. ICON vs CVKD Comparison

ICON vs CVKD Comparison

Compare ICON & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Icon Energy Corp.

ICON

Icon Energy Corp.

HOLD

Current Price

$1.03

Market Cap

3.3M

Sector

N/A

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$1.09

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICON
CVKD
Founded
2023
2022
Country
Greece
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
4.0M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
ICON
CVKD
Price
$1.03
$1.09
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $14.00
AVG Volume (30 Days)
29.0K
★ 151.5K
Earning Date
08-14-2026
11-09-2026
Dividend Yield
★ 5092.64%
N/A
EPS Growth
N/A
★ 23.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$57.25
N/A
Revenue Next Year
$3.95
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.82
52 Week High
$4.23
$14.21

Technical Indicators

Market Signals
Indicator
ICON
CVKD
Relative Strength Index (RSI) 57.50 47.32
Support Level $0.84 $1.00
Resistance Level $1.12 $1.36
Average True Range (ATR) 0.09 0.11
MACD 0.00 0.03
Stochastic Oscillator 93.22 80.68

Price Performance

Historical Comparison
ICON
CVKD

About ICON Icon Energy Corp.

Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users. The cargos carried by the company are Grains, Minerals, Iron Ore, Coal and Bauxite.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: